𝔖 Bobbio Scriptorium
✦   LIBER   ✦

306 DOCETAXEL (DOC) AND MITOXANTRON (MIT) IN THE MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER (HRPCA)

✍ Scribed by C.H. Ohlmann; K. Breitenbach; D. Pfister; U. Engelmann; A. Heidenreich

Book ID
119617638
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
316 KB
Volume
6
Category
Article
ISSN
1569-9056

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Activity of second-line chemotherapy in
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
✍ Jonathan E. Rosenberg; Vivian K. Weinberg; W. Kevin Kelly; Dror Michaelson; Maha πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 147 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second‐line chemotherapy for taxane‐refractory, hormone‐refractory, prostate cancer (HRPC). ## METHODS. Patients with HRPC that progressed during or wi